1. Metabolic Enzyme/Protease
  2. RAR/RXR


The nuclear retinoic acid receptors (RARs) are transcriptional transregulators, which control the expression of specific gene subsets subsequently to ligand binding and to strictly controlled phosphorylation processes. RARs consist of three subtypes, α (NR1B1), β (NR1B2) and γ (NR1B3), encoded by separate genes. RARs function as ligand-dependent transcriptional regulators, heterodimerized with retinoid X receptors (RXRs), which also consist of three types, α NR2B1, β (NR2B2) and γ (NR2B3). RARs play critical roles in a variety of biological processes, including development, reproduction, immunity, organogenesis and homeostasis, as assessed by vitamin A-deficiency (VAD), pharmacological and genetic studies conducted in the mouse.

Retinoid X receptor (RXR) belongs to a family of ligand-activated transcription factors that regulate many aspects of metazoan life. A class of nuclear receptors requires RXR as heterodimerization partner for their function.

RAR/RXR Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-14649
    Retinoic acid Agonist 98.36%
    Retinoic acid is a natural agonist of RAR/RXR nuclear receptors. Retinoic acid also bind to PPARβ/δ, with Kd of 17 nM.
  • HY-14171
    Bexarotene Agonist 99.81%
    Bexarotene (Targretin) is a selective RXR agonist approved for the treatment of CTCL.
  • HY-14652
    Tamibarotene Agonist 99.77%
    Tamibarotene is an agonist for retinoic acid receptor α/β, and used for cancer treatment.
  • HY-10475
    AM580 Agonist 99.41%
    AM580 is a stable retinobenzoic derivative, and originally synthesized as a RARα agonist.
  • HY-14799
    Palovarotene Agonist 98.27%
    Palovarotene is a nuclear retinoic acid receptor γ (RAR-γ) agonist.
  • HY-14802D
    (-)-Talarozole Inhibitor 98.02%
    (-)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
  • HY-14802C
    (+)-Talarozole Inhibitor 99.28%
    (+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
  • HY-107765
    LY2955303 Antagonist 98.25%
    LY2955303 is a potent and selective retinoic acid receptor gamma (RARγ) antagonist with a Ki of 1.09 nM.
  • HY-15373
    Fenretinide Inhibitor 99.41%
    Fenretinide is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.
  • HY-16681
    AGN 194310 Agonist 98.26%
    AGN 194310(VTP-194310) is a potent and selective pan-RARs agonist with Kd values of 3/2/5 nM for RARα/β/γ respectively.
  • HY-15127
    Isotretinoin Inhibitor 99.77%
    Isotretinoin(13-cis-Retinoic acid) is a medication used for the treatment of severe acne. It was first developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.
  • HY-15388
    Tazarotene Agonist 99.29%
    Tazarotene is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris.
  • HY-15682
    TTNPB Agonist 99.31%
    TTNPB is a highly potent RAR agonist. Competitive binding assays using human RARs yield IC50s of α=5.1 nM, β= 4.5 nM, and γ=9.3 nM, respectively.
  • HY-B0107
    Acitretin Agonist 99.56%
    Acitretin(Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis.
  • HY-B0091
    Adapalene Agonist >98.0%
    Adapalene(CD-271; Differin), a synthetic retinoid, is a retinoic acid receptor agonist (RAR).
  • HY-101106
    AR7 Antagonist 98.77%
    AR7 is a retinoic acid receptor α (RARα) antagonist.
  • HY-N0163
    Magnolol Agonist 99.91%
    Magnolol, the main polyphenol compound of the bark of Magnolia officinalis, has a variety of pharmacological activities.
  • HY-16684
    AGN 195183 Agonist 98.10%
    AGN 195183 is a potent and selective agonist of RARα(Kd=3 nM) with improved binding selectivity relative to AGN 193836; no activity on RARβ/γ.
  • HY-10291
    (R)-Flurbiprofen Inhibitor 99.23%
    (R)-Flurbiprofen is the R-enantiomer of the racemate NSAID Flurbiprofen, (R)-Flurbiprofen inhibits the binding of [3H]9-cis-RA to RXRα LBD with IC50 of 75 μM.
  • HY-16683
    AGN 205728 Antagonist
    AGN 205728 is a potent and selective RARγ antagonist with Ki/IC95 values of 3 nM/ 0.6 nM; no inhibiton on RARα and RARβ.